News Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
28.74 ^CNY	-3.94%		-1.17%	-44.81%

Apr. 26	Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	China Stocks Fall Ahead of March Economic Data Release	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
China Stocks Fall Ahead of March Economic Data Release	Apr. 08	MT
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%	Apr. 08	MT
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets	Feb. 23	MT
Hinova Pharmaceuticals Gets US FDA's Nod to Conduct Phase II Clinical Trial on HP501 Tablets	Dec. 07	MT
Hinova Pharmaceuticals Gets Nod to Test Prostate Cancer Drug	Nov. 03	MT
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hinova Pharmaceuticals to Resubmit Application for Deuterated Enzalutamide Soft Capsules	23-10-23	MT
Hinova Pharmaceuticals Inc.(XSSC:688302) added to S&P Global BMI Index	23-09-18	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange Composite Index	23-04-13	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange A Share Index	23-04-13	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Hinova Pharma Gets Regulatory Nod for Anti-Tumor Drug Trial	23-02-10	MT
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment	23-02-06	CI
Hinova Pharmaceuticals Gets FDA's Nod to Hold Trial on Anti-Cancer Drug; Shares Jump 5%	23-02-01	MT
MagicRNA announced that it has received $2.900000 million in funding from Goldport Capital, Shenzhen Credit Guarantee Group Co., Ltd, Hinova Pharmaceuticals Inc., NLPE, Shenzhen Hongtao Fund Management Co., Ltd. and other investors.	22-12-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

Summary

Filters